Main publications
- Sarkozy, C. et al. (2021) Innovative therapies based on molecular orientation in patients with relapse and refractory diffuse large B-cell lymphoma: Results of LNH-EP1 study. V. Am J Hematol;96(10):E376-E379
- El Halabi, L. et al. (2021) Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk;21(4):257-266.
- Khalife-Hachem, S. et al. (2021) Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. Hemasphere;5(9):e632.
- Willekens, C. et al. (2021) Effects of azacitidine in 93 patients with IDH1/2 mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Leuk Lymphoma;62(2):438-445.
- Saleh, K. et al. (2020) Burkitt and Burkitt-Like Lymphomas: a Systematic Review. Curr Oncol Rep;22(4):33.
- Khalife-Hachem, S. et al. (2020) Spontaneous molecular response of IDH2 acute myeloid leukemia. Ann Hematol;99(2):353-354.
- Flieswasser, T. et al. (2019) Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method. Cancers (Basel);11(10):1611.
- Roos-Weil, D. et al. (2019) A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. Cancer Discov;9(6):796-811.
- Willekens, C. et al. (2018) Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia;32(9):2008-2081.
- Quek, L. et al. (2018) Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med;24(8):1167-1177.
- Popovici-Muller, J. et al. (2018) Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med Chem Lett;9(4):300-305.
- Yen, K. et al. (2017) AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations. Cancer Discov;7(5):478-493.
- Poinsignon, V. et al. (2016) Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. J Chromatogr B Analyt Technol Biomed Life Sci;1022:290-297.
Catégorie de la page:
